Malignant Ascites Treatment Market – Increasing investments in research of treatment worldwide by manufacturers is expected to boost the growth of the market| BioVie, BD, Medtronic plc

๐†๐ฅ๐จ๐›๐š๐ฅ ๐Œ๐š๐ฅ๐ข๐ ๐ง๐š๐ง๐ญ ๐€๐ฌ๐œ๐ข๐ญ๐ž๐ฌ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ ๐Œ๐š๐ซ๐ค๐ž๐ญ

Ascites is the condition characterized by formation of excessive fluid in the abdominal cavity, particularly in the peritoneal cavity. It causes when the body is unable to eliminate out fluids. When ascites is developed due to cancer, it is called as malignant peritoneal effusion or malignant ascites. Malignancies that are most commonly associated with malignant ascites are breast, liver, lungs, lymphoma, and colon cancers. In ascites condition, lymph glands in the body gets blocked and lead to ascites symptoms including low blood pressure, loss of sleep, fatigue, and skin problems. The key symptoms of malignant ascites include abdominal pain or discomfort, shortness of breath, swelling of the abdomen, leg or ankle swelling, constipation, and weight gain. Diagnosis of ascites can be done by ultrasound, x-ray test, CT scans, and physical examination. The survival rate of these patients is very low, although many suitable treatments, such as paracentesis, chemotherapy, and surgeries, are available. Various conventional treatments for malignant ascites include chemotherapy, shunting, paracentesis, and use of drugs, such as spironolactone and spironolactone. Cirrhosis of the liver is the most common cause of ascites but other conditions such as kidney failure, heart failure, cancer or infection can also cause ascites.

๐“๐จ ๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐๐ƒ๐… ๐๐ซ๐จ๐œ๐ก๐ฎ๐ซ๐ž ๐‡๐ž๐ซ๐ž @ย https://www.coherentmarketinsights.com/insight/request-pdf/1775

๐†๐ฅ๐จ๐›๐š๐ฅ ๐Œ๐š๐ฅ๐ข๐ ๐ง๐š๐ง๐ญ ๐€๐ฌ๐œ๐ข๐ญ๐ž๐ฌ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ ๐Œ๐š๐ซ๐ค๐ž๐ญ โ€“ ๐ƒ๐ฒ๐ง๐š๐ฆ๐ข๐œ๐ฌ

Rising prevalence of cirrhosis is a major factor boosting the growth of the global malignant ascites market. According to a study published in the World Journal of Gastroenterology in 2011, over 50% of patients worldwide develop ascites within ten years of diagnosis. In a published article in the Journal of Clinical and Translational Hepatology, it was highlighted that advancements in the ascites condition is associated with poor prognosis, with a mortality of 15% in one year and around 44% in a five-year follow-up. Moreover, favorable reimbursement policies, such as the 2010 Patient Protection and Affordable Care Act (PPACA), along with increasing incidence of cancer, are propelling the global market growth. For instance, in 2016, NanoAntibiotics acquired LAT Pharma LLC, an early-stage biotechnology company famous for developing new medicines, to treat life-threatening complications of liver cirrhosis.

However, stringent regulations and complications associated with ascites treatment such as internal bleeding after paracentesis treatment, exposure of radiation in chemotherapy may hinder growth of the market over the forecast period. For instance, in the Experimental & Molecular Medicine journal, it was shown that radiation can induce toxicities in non-tumorous liver tissues that may limit the course of therapy or lead to chronic side effects, including late fibrosis.

๐“๐จ ๐†๐ž๐ญ ๐ฆ๐จ๐ซ๐ž ๐ข๐ง๐Ÿ๐จ๐ซ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐‘๐ž๐ช๐ฎ๐ž๐ฌ๐ญ ๐Ÿ๐จ๐ซ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐š๐ญ โ€“https://www.coherentmarketinsights.com/insight/request-sample/1775

๐†๐ฅ๐จ๐›๐š๐ฅ ๐Œ๐š๐ฅ๐ข๐ ๐ง๐š๐ง๐ญ ๐€๐ฌ๐œ๐ข๐ญ๐ž๐ฌ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ ๐Œ๐š๐ซ๐ค๐ž๐ญ โ€“ ๐‘๐ž๐ ๐ข๐จ๐ง๐š๐ฅ ๐ˆ๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ

North America accounts for the largest share in the global malignant ascites treatment market size, owing to high healthcare expenditure, well-developed technology, and increasing prevalence of cirrhosis are accelerating growth of the malignant ascites treatment market in this region. For instance, according to study published in 2015 Journal of Clinical Gastroenterology showed prevalence of cirrhosis in the U.S. was approximately 0.27%, corresponding to 633,323 adults.

Moreover, Asia Pacific is expected to witness significant growth in the market over the forecast period, owing to increasing prevalence of cirrhosis. As per a 2015 study published in the BMJ Open Gastroenterology report, the rate of hospitalization due to viral hepatitis cirrhosis decreased by 10% between 2006 and 2010. However, non-viral hepatitis cirrhosis and alcoholic cirrhosis exhibited an increase of 35% and 33% in China.

๐†๐ฅ๐จ๐›๐š๐ฅ ๐Œ๐š๐ฅ๐ข๐ ๐ง๐š๐ง๐ญ ๐€๐ฌ๐œ๐ข๐ญ๐ž๐ฌ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ ๐Œ๐š๐ซ๐ค๐ž๐ญ โ€“ ๐‚๐จ๐ฆ๐ฉ๐ž๐ญ๐ข๐ญ๐ข๐ฏ๐ž ๐Ž๐ฎ๐ญ๐ฅ๐จ๐จ๐ค

The key players operating in the global malignant ascites treatment market include PharmaCyte Biotech Inc., Sequana Medical, Fresenius SE & Co. KGaA, BioVie, BD, Medtronic Plc, and GI Supply, Actavis Elizabeth LLC, Mylan Pharmaceuticals Inc., GE Healthcare, Trion Pharma, Siemens AG, and Fresenius Biotech.

These players are currently adopting a range of strategies, including collaborations, and increasing their R&D funding to strengthen their product portfolios and retain their positions in the global market. For instance, BioVieโ€™s Lead Compound BIV201 received the FDA Orphan-Drug Designation for the treatment of ascites in the year 2016.

๐…๐จ๐ซ ๐Œ๐จ๐ซ๐ž ๐ˆ๐ง๐Ÿ๐จ๐ซ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐จ๐ซ ๐๐ฎ๐ž๐ซ๐ฒ ๐จ๐ซ ๐‚๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐š๐ญ๐ข๐จ๐ง ๐›๐ž๐Ÿ๐จ๐ซ๐ž ๐๐ฎ๐ฒ๐ข๐ง๐ , ๐•๐ข๐ฌ๐ข๐ญ ๐š๐ญ โ€“https://www.coherentmarketinsights.com/insight/talk-to-analyst/1775

๐Œ๐š๐ซ๐ค๐ž๐ญ ๐“๐š๐ฑ๐จ๐ง๐จ๐ฆ๐ฒ

Based on treatment type:
โ€ข Therapeutic Treatment
โ€ข Surgical Treatment

In terms of application:
โ€ข Ovarian Cancer
โ€ข Breast Cancer
โ€ข Gastrointestinal Cancer
โ€ข Colorectal Cancer
โ€ข Carcinoma of Unknown Primary
โ€ข Others

By geography:
โ€ข North America
โ€ข Latin America
โ€ข Europe
โ€ข Asia Pacific
โ€ข Middle East
โ€ข Africa

๐“๐จ ๐ƒ๐ข๐ซ๐ž๐œ๐ญ ๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž ๐ญ๐ก๐ข๐ฌ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐‘๐ž๐ฉ๐จ๐ซ๐ญ โ€“ย https://www.coherentmarketinsights.com/insight/buy-now/1775

Contact US:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

close

Sign up for the New Frontier Report

Get regularly updated reports detailing stocks recommendations and new economic shifting industries and technologies.

We donโ€™t spam! Read our privacy policy for more info.